Results 301 to 310 of about 38,272 (314)

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Lancet Diabetes and Endocrinology,the, 2021
Niels Jongs, Glenn Chertow, John J V Mcmurray   +2 more
exaly  

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Lancet Diabetes and Endocrinology,the, 2020
David Z I Cherney, Claire C J Dekkers, Abdul Halim Abdul Gafor   +2 more
exaly  

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2010
Clifford J Bailey
exaly  

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Kidney International, 2020
Erik J M Van Bommel, Marcel H A Muskiet, Lennart Tonneijck   +2 more
exaly  

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Lancet Diabetes and Endocrinology,the, 2017
Paresh Dandona, Chantal Mathieu, Moshe Phillip   +2 more
exaly  

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

European Journal of Heart Failure, 2019
John J V Mcmurray, David L Demets, Lars Køber   +2 more
exaly  

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

Journal of Clinical Endocrinology and Metabolism, 2012
Jan Bolinder, John Wilding
exaly  

Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes, Obesity and Metabolism, 2013
Dick de Zeeuw
exaly  

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Kidney International, 2014
Paola Fioretto
exaly  

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

Nature Medicine, 2015
Caroline Bonner, Iuliana Popescu, Abdullah Sener   +2 more
exaly